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ARTICLE
HIV envelope V3 region mimic embodies key
features of a broadly neutralizing antibody lineage
epitope
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Mattia Bonsignori2,3, Baptiste Aussedat6, William E. Walkowicz6, Therese Ton7, Jeffrey O. Zhou8,
Samuel Danishefsky6, Barton F. Haynes2,3 & Stephen C. Harrison1,9
HIV-1 envelope (Env) mimetics are candidate components of prophylactic vaccines and
potential therapeutics. Here we use a synthetic V3-glycopeptide (“Man9-V3”) for structural
studies of an HIV Env third variable loop (V3)-glycan directed, broadly neutralizing antibody
(bnAb) lineage (“DH270”), to visualize the epitope on Env and to study how afﬁnity
maturation of the lineage proceeded. Unlike many previous V3 mimetics, Man9-V3 encom-
passes two key features of the V3 region recognized by V3-glycan bnAbs—the conserved
GDIR motif and the N332 glycan. In our structure of an antibody fragment of a lineage
member, DH270.6, in complex with the V3 glycopeptide, the conformation of the antibody-
bound glycopeptide conforms closely to that of the corresponding segment in an intact HIV-1
Env trimer. An additional structure identiﬁes roles for two critical mutations in the devel-
opment of breadth. The results suggest a strategy for use of a V3 glycopeptide as a vaccine
immunogen.-
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M imicry of three-dimensional (3D) protein surfaces is apotentially valuable strategy for probing and modulat-ing protein−protein interactions. Peptide mimetics
have been explored for drug development and vaccine research in
a wide variety of contexts (reviewed in Gross et al.1). The highly
immunogenic third variable loop (V3) of the HIV-1 envelope
protein (Env) is a plausible target of such efforts2, but glycosy-
lation at two or more V3-loop positions in the native trimer3–7
has limited the scope of previous work.
The Env V3 loop, parts of which are less variable than other
“variable” loops on the Env gp120 subunit, is almost always ~35
residues long. Its tip bears a conserved 312-GPGR/Q-315 sequence
motif, and its base includes a conserved 324-GDIR-327 motif with
an N-linked glycan frequently present at position 332 (HXB2
numbering scheme)8. Members of the V3-glycan class of broadly
neutralizing antibodies (bnAbs) penetrate the Env “glycan shield”
and contact both carbohydrate and protein components at the V3
loop base, which includes the GDIR motif9. These bnAbs usually
require a glycan at N332 for high afﬁnity, and some of them also
require other glycans, such as one at N301. Thus, members of this
class of bnAbs can have different modes of Env recognition9–14.
The potency and breadth of antibodies that bind this site have
made their elicitation a high priority for immunogen design15, 16.
Certain glycans on HIV Env, like most glycoproteins, are
heterogeneous and are usually expressed as a population of gly-
coforms17 (glycosylation variants). While the N332 and N301
glycans are part of an oligomannose patch on HIV Env18, 19, the
types of glycan processing, or lack thereof, at this site are
determined by steric environment. Moreover, complex-type gly-
cans are inﬂuenced by the glycosyltransferase activities of the cell
in which they are produced18. Thus, alterations of HIV Env could
alter the glycan types at N332 and N301. Such heterogeneity
creates a vaccine-design challenge that extends to any glycosy-
lated immunogen20. Chemical synthesis of glycopeptides can in
principle overcome this hurdle, by generating glycopeptides with
homogeneous glycosylation patterns21. Moreover, in the speciﬁc
case of the HIV-1 Env V3 loop, a synthetic mimic of a “minimal”
loop could also present the bnAb epitope without interference
from other surface features—e.g., the nearby gp120 V1V2 loop,
which can interfere with V3 loop recognition22, 23.
A synthetic V3-loop glycopeptide (“Man9-V3”), described
recently, presents the conformational epitopes needed for the
binding of N332 glycan-dependent bnAbs24, 25. The peptide
design derives from the JRFL mini-V3 gp120 outer domain, used
previously for determining a crystal structure with the Fab of
bnAb PGT1289. The synthetic V3 glycopeptide, which has Man9
glycans (Man9GlcNAc2) at N332 and N30124 and a 14-residue tip
deleted, was used to identify the V3-glycan bnAb DH270.6
(12.9% mutated nucleotides and 71% neutralization breadth12) by
labeling the B-cell receptor (BCR) on cells from the HIV-1
infected donor CH848; the antibody is part of a previously
described lineage from this individual (Fig. 1a)12.
We describe here a high-resolution crystal structure of “Man9-
V3” bound with the single chain variable fragment (scFv) of the
N332-glycan dependent bnAb, DH270.6. We have also deter-
mined a structure of the Fab of a clonally related member of this
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Fig. 1 Antibody and virus data. a DH270 clonal lineage tree. b Sequence logo of the V3 region of CH848 autologous viruses. The beginning and end of the
GDIR motif are indicated. The frequency of each amino acid at each site is indicated by its height
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lineage, DH270.3 (11.8% mutated nucleotides and 42% neu-
tralization breadth), in complex with a synthetic Man9 glycan26.
These clonally related antibodies have similar numbers of
mutation, but their neutralization breadth and potency differ
substantially. Through structural analysis of these two related
antibodies, we can account for differences in breadth and afﬁnity
between the branches of the lineage from which these two anti-
bodies derive and understand the somatic mutation events that
led to enhanced binding afﬁnity and neutralization breadth.
Our structures account for the roles of two low probability
somatic mutations, introduced at different stages during antibody
afﬁnity maturation that correlate with an increase in neutraliza-
tion breadth. The mutated residues anchor DH270 lineage
members onto the V3 loop GDIR region and contact the high
mannose moiety of the N332 glycan. These interactions resemble
those made by PGT124 and PGT128, which target the same Env
epitope9, 10, 27, but the epitope contacts by DH270-lineage
members are with different complementarity determining regions
(CDRs) and different amino-acid residues. We further show that
the synthetic V3 glycopeptide is a mimic of the V3 region of an
intact Env trimer and suggest that it might be useful both as an
immunogen and as a probe for determining interactions between
other antibodies and HIV Env.
Results
Crystal structure of the DH270.6-Man9-V3 complex. To char-
acterize the binding site (epitope) for DH270 lineage members at
a higher resolution than previously reported12, we crystallized an
scFv of DH270.6 in complex with the synthetic Man9-V3 glyco-
peptide and determined its structure at 2.17 Å resolution (Fig. 2a,
b, Supplementary Fig. 1). We built the complete glycopeptide into
the electron density map, along with the entire N332 glycan
(Man9GlcNAc2) and the ﬁrst three reducing-end carbohydrate
residues at N301, the two N-acetylglucosamines (GlcNAc2) and
core mannose. As expected from its conformation in the Env
trimer, Man9-V3 formed a two-stranded β-hairpin with a bulge at
the conserved 324GDIR327 motif (Fig. 2b). The N332 Man9 was
well ordered, except for the terminal mannose residue of the D2
arm.
In the crystal structure, the antibody engaged the Man9-
V3 glycopeptide residues I322 to N332, the N332 glycan D1 and
D3 arms, and the N301 GlcNAcs and core mannose. The
conformations of the CDRs of the unliganded DH270.612 are the
same as those seen in the complex; the superposition of
unliganded and complexed DH270.6 gave a Cα root mean square
deviation (r.m.s.d.) of 0.7 Å, showing that the antibody had not
undergone large-scale conformational change upon binding to
Man9-V3. Differences in the side-chain conformations of R57H,
Y105H, and Y106H, which contact the peptide or N332 glycan, are
discussed below.
The structure of the complex shows that there are two major
regions of antibody–glycopeptide interactions: (1) the Env
324GDIR327 motif (Fig. 1b), which is an important anchor point
for binding N332-glycan dependent bnAbs, makes extensive
contacts with the CDRH2 and CDRH3 loops of DH270.6, and (2)
the N332-Man9, which makes extensive contacts with the
antibody CDRH3 and CDRL2 loops.
Conformation of the Man9-V3 glycopeptide. Superposition of
our structure on that of the BG505 SOSIP.664 in complex with
PGT12827 shows that the conformation of the synthetic glyco-
peptide is very close to that of the V3 loop in an intact, BG505
trimer (Fig. 3a), with a Cα r.m.s.d. of 1.31 Å. The conformation of
the Man9-V3 glycopeptide is similar to those of V3 loops in other
HIV Env trimers from various strains, both when unliganded and
when bound with different V3-glycan-dependent antibodies
(Fig. 3b, Supplementary Table 1), with Cα r.m.s.d.’s of less than
1.15 Å for all structures superposed. Glycopeptide–antibody
contacts are therefore likely to represent those made with Env by
the DH270 lineage antibodies. Moreover, the conformational
similarity suggests that the synthetic V3 glycopeptide might be a
useful immunogen, consistent with biochemical data previously
reported24.
Further evidence that Man9-V3 is a good mimic of the V3
region of an intact trimer comes from a 3D reconstruction from
EM images of negatively stained DH270.6 Fab in complex with
the 92BR SOSIP.664 trimer used in our previous work on
DH270.112 (Supplementary Fig. 2). As expected, three DH270.6
Fabs bound to each trimer, and there were no gross conforma-
tional differences between this trimer and the BG505 SOSIP.664
in complex with PGT12827. When we superposed the glycopep-
tide onto the V3 region of the trimer model, the DH270.6 scFv ﬁt
well into Env-proximal Fab density in the EM map (Supplemen-
tary Fig. 2).
We probed the Man9-V3 structure in the absence of a binding
partner by one-dimensional (1D) nuclear magnetic resonance
(NMR) spectroscopy. The methyl region of the spectrum showed
11 well-resolved peaks with substantial chemical-shift dispersion
(Supplementary Fig. 3A). Man9-V3 has eight residues with
methyl groups that could contribute to those peaks (5 Ile, 2 Thr,
and 1 Ala) (Supplementary Fig. 3B). Although those residues
would contribute a total of 13 methyl peaks, some probably
overlap, reducing the distinguishable peaks to 11. Five isoleucine
side chains contribute 10 of the 13 methyl groups in different
regions of the glycopeptide (some are in the β-hairpin and others
are in the GDIR bulge) (Supplementary Fig. 3B). The spectrum
thus indicates distinct chemical environments for at least four of
the ﬁve isoleucine residues (since the other three peaks from the
spectrum could derive from the threonine or alanine side chains)
and hence substantial non-random structure. The result is
compatible with the interactions of isoleucine side chains seen
in the crystal structure (e.g., Fig. 2c, Supplementary Fig. 3B).
Addition of dithiothreitol to reduce the disulﬁde bond diminished
the chemical-shift dispersion (Supplementary Fig. 3A), consistent
with our inference from the structure that the disulﬁde, which is
present in native Env, stabilizes the Man9-V3 β-hairpin.
We generated additional evidence that Man9-V3 has native-like
ordered structure in solution by measuring the kinetics of
DH270.6 Fab binding with the peptide and comparing the results
with the kinetics of its binding with monomeric gp120 (Table 1,
Supplementary Fig. 4A, 4B). The association rates for the two
complexes were comparable, showing that Man9-V3 did not need
to undergo a slow folding step before stable association with the
Fab; the equilibrium dissociation constants for peptide and gp120
were likewise similar. These data suggest that the conformation of
the unbound peptide resembled that of the corresponding
segment in intact gp120. The association rate constants are
nonetheless lower than those of rapid, diffusion-limited protein
associations, consistent with an initial, moderately slow, con-
formational adjustment in both cases.
Interaction with V3 peptide and G57R mutation signiﬁcance.
Somatic hypermutation is biased by the preference of the
activation-induced cytidine deaminase (AID) for certain micro-
sequence motifs (“hot spots”)28, 29. Base substitution during
somatic hypermutation also depends on surrounding sequences.
Previous studies showed that the DH270 lineage acquired a G57R
mutation in the CDRH2 loop between the DH270 unmutated
common ancestor (“UCA”) and the early intermediate, “IA4”12.
Since the nucleotide sequence at the site of mutation (GGC) is an
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03565-6 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1111 | DOI: 10.1038/s41467-018-03565-6 |www.nature.com/naturecommunications 3
unlikely target for AID, this site is called an AID “cold spot” (a
common cold spot microsequence generally represented by GRS,
where R is a purine and S is either a C or a G and the underlined
residue is the one that gets mutated), and a mutation at a site like
this one is a rare event28, 30. Introducing the G57R mutation
alone into the germline-reverted DH270 UCA conferred detect-
able binding to autologous Env and heterologous neutralization,
implying that acquisition of the low probability mutation was
critical to initiate the observed breadth of the lineage.
The side chain of R57H recognizes the 322–325 bulge in the V3
loop by donating hydrogen bonds to the main-chain carbonyls of
I322 and G324. These contacts anchor the antibody–peptide
interaction, much like the backbone contacts observed between
the 324GDIR327 motif and PGT128 CDRH2 and CDRH3 loops9
or those between the side chain of D325 and the PGT124 CDRL1,
CDRL3, and CDRH3 loops11 (Fig. 2c, Supplementary Fig. 5A,
5B). Previous studies showed that an R57GH mutation in DH270.
IA4 completely eliminates binding to HIV Env, illustrating the
importance of this interaction12. The R57H interaction with the
V3 loop differentiates 324GDIR327-motif recognition by DH270
lineage members from its recognition by other well-characterized,
N332-glycan dependent bnAbs9, 11, 31.
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In addition to interactions through R57H, DH270.6 forms an
extended network of polar contacts with the 324GDIR327 motif,
further distinguishing antibodies in this lineage from other
V3-glycan bnAbs. In particular, N52 in the CDRH2 loop donates
a hydrogen bond to the D325 carboxylate, ﬁxed in its side-chain
conformation by a salt bridge with R327, and D107 in the
CDRH3 loop accepts a hydrogen bond from the D325 backbone
amide (Fig. 2c). The R327 guanidinium group also hydrogen
bonds with S103H. Mutating D325 to Arg leads to a complete loss
of detectable binding to HIV-1 Env, conﬁrming the importance of
this residue for antibody recognition12. The Env R327A mutant
has only a slightly lower afﬁnity for DH270.6 than its wild-type
counterpart (Fig. 4a), while the S103G mutation weakens the Env
interaction twofold (Fig. 4b, Table 2). Thus, for the DH270
lineage, contacts with the GDIR peptide backbone (by R57H and
D107H) and with the D325 side chain (by N52H) are essential
sites of interaction with the conserved anchor region of Env V3;
the antibody–R327 interaction is a less critical, secondary contact
point.
Interaction of DH270.6 with N332 Man9 glycan. N332-glycan-
dependent bnAbs typically have a long CDR loop that can contact
both glycan and protein residues. DH270 lineage members have
shorter CDRs than other bnAbs of the same class12, but it is
nonetheless their longest CDR, the CDRH3, that contacts the V3
peptide. In our Man9-V3:DH270.6 structure, the N332 glycan and
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Fig. 3 HIV trimer V3 region compared to V3 glycopeptide. a Superposition of the V3 glycopeptide (red) from the DH270.6-Man9-V3 complex onto the V3
region (cyan) of the PGT128-BG505 complex (PDB ID: 5ACO). Glycans from the DH270.6-Man9-V3 complex are shown as green sticks. b Superposition
of V3 glycopeptide (red) from the DH270.6-Man9-V3 complex onto the V3 region of other HIV Envs (both in complex, and unliganded) (PDB ID’s 4ZMJ47,
5CEZ10, 5I8H48, 5FYK49, 5FYJ49, 5T3S50, 5V8L51, 5T3Z52)
Table 1 Rate constants and equilibrium dissociation
constants for binding of DH270.6 Fab with Man9-V3 and
with gp120
ka (M-1s-1) kd (s-1) KD (μM)
Man9-V3+
DH270.6 Fab
1.0 ± 0.05×104 (0.07 ± 0.005) 7 ± 0.4
gp120+DH270.6
Fab
0.9 ± 0.2×104 (0.01 ± 0.04) 1.2 ± 0.3
Association rate constants (ka) and equilibrium dissociation constants (KD) were determined
from duplicate BLI measurements at ﬁve concentrations (Supplementary Fig. 4). Dissociation
rate constants were calculated as the products of ka and KD. Errors are SEM
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the V3 peptide sandwich the CDRH3 loop, which has extensive
interactions, both polar and non-polar, with the glycan (Fig. 2d).
One key polar interaction appears to be a bidentate contact
between D115H in CDRH3 and the C-mannose moiety of the D1
arm of N332-Man9. Similar contacts with D1-arm mannoses have
been seen in PGT124 and PGT128 complexes9, 11. Mutation of
D115H to alanine in DH270.1 reduces Env afﬁnity12. Spatially
adjacent to the D115H-mannose interaction is a contact from
Y48L of the CDRL2 loop, which hydrogen bonds with the same
mannose. We mutated Y48L to leucine, which is found in the
UCA of this lineage, and found fourfold lower afﬁnity for 92BR
SOSIP.664 Env trimer (Fig. 4b, Table 2). The N332 glycan also
stacks against Y51L, a germline-encoded residue, which is nearby.
Because the Y51L residue is germline encoded (i.e. present in the
DH270 UCA) and is in the same conformation as in the later
antibody lineage members, it would not have been a principal
contributor to afﬁnity maturation.
DH270.6 residues engaged in hydrophobic contacts between
CDRH3 and the N332 Man9 glycan include W101H, Y105H, and
Y106H (Fig. 2d). The Y105H and Y106H side chains are
disordered in the unliganded DH270.6 structure12. In the
complex however, Y105H inserts into a groove near H330 of V3
and the core GlcNAc of the N332 glycan while Y106H is in
hydrophobic contact with the second GlcNAc and the adjoining
mannose residue. Mutation of these antibody residues reduces
Env binding12. E52L and S58L also contact D1 arm mannose
residues, but these, like Y51L, are germline-encoded, and probably
do not provide an advantage to later antibody lineage members
for Env recognition.
DH270 lineage antibodies also interact with the D3 arm of the
N332 Man9 glycan and the GlcNAcs and core mannose of the
N301 glycan; the latter interaction is less extensive, consistent
with observations showing it to be dispensable for Env binding
and viral neutralization12. The side chain of D31H in the antibody
CDRH1 loop appears to contact the terminal mannose of the D3
arm, although density for this arm is not as strong as for the D1
arm mannoses. We previously showed that mutating this residue
in the antibody reduces Env afﬁnity12. Interaction with this
terminal, D3-arm mannose, along with those of the D1 arm,
shows why high-mannose glycans are critical for interactions with
late members of this antibody lineage.
DH270.3-Man9 complex identiﬁes a critical mutation. Anti-
body DH270.3, in a different branch of the lineage than
DH270.6, is both less potent against autologous and hetero-
logous viruses and has a narrower neutralization spectrum
(Fig. 1a). We determined a crystal structure of DH270.3 bound
with a synthetic, biotinylated Man9 glycan24. In the density map
at 2.85 Å resolution, all of the Man9 sugar moieties were well
resolved, and the reﬁned model showed that they superpose well
on the N332-Man9 glycan from our structure of DH270.6 bound
with Man9-V3, except for the terminal mannose of the D2 arm,
which does not contact either antibody (Fig. 5a). The con-
formation of the N332-Man9 glycan in our structures does,
however, differ from that of other N332-glycan bnAb complexes
(Supplementary Fig. 6), illustrating the conformational ﬂex-
ibility of these carbohydrates and showing that antibody CDRs
can induce conformational shifts in HIV Env glycans. In con-
trast, the conformation of the V3 region, which is probably more
rigid than the glycans, varies little from structure to structure. In
any case, the DH270.3-Man9 structure conﬁrms the contacts we
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Fig. 4 Binding of DH270.6 and Env. Biolayer interferometry association and dissociation curves are shown for a wild-type (KD= 2.76 nM) and R327A
mutant (KD= 7.64 nM) forms of 92BR SOSIP.664 Env tested with DH270.6 Fab at the indicated concentrations and b wild-type and mutant forms of
DH270.6 Fab binding to wild-type 92BR SOSIP.664
Table 2 Dissociation constants of Fab complexes with wild-
type 92BR SOSIP.664
KD (nM)
DH270.6 WT 11 ± 1
DH270.6 Y48LL 44 ± 2
DH270.6 T98RH 46 ± 2
DH270.6 S103GH 19 ± 1
Errors are SEM, determined from duplicate measurements
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observed between DH270.6 and the N332-glycan, and shows a
conserved mode of glycan recognition by these clonally related
antibodies.
The one notable difference between the two structures is at
D115H. This residue of the DH270.3 antibody forms a salt bridge
with R98H, rather than the bidentate interaction with a terminal
mannose seen in the DH270.6 complex. (Figs. 2d, 5b, Supple-
mentary Fig. 7). DH270.6 has threonine instead of arginine at
position 98H. When we reverted T98H in DH270.6 to Arg, we
detected only negligible residual binding with 92Br SOSIP.664
Env trimer (Fig. 4b). Thus, the arginine appears to “distract”
D115H from interacting with the glycan, and its somatic mutation
to Thr (another low probability event: Fig. 5c) correlates with
development of breadth, probably by allowing D115H to interact
with a terminal mannose instead of with another residue in the
antibody.
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Discussion
The structure of the DH270.6-Man9-V3 complex shows that this
glycopeptide accurately mimics the V3 region of an intact native-
like HIV Env trimer—a result consistent with previous data24.
The high speciﬁcity of these antibodies for the peptide motifs and
the homogeneity of synthesized glycopeptides makes them useful
tools for dissecting protein−protein interactions and for immu-
nogen design. The Man9-V3 glycopeptide used in our studies
included a larger portion of the V3 region than present in pre-
viously reported V3 mimics3–7, and also included two critical
glycans, at N332 and N301, often contacted by V3-glycan
“supersite” bnAbs. Inclusion of glycans in a peptide mimetic is
clearly important for analyzing protein contacts in which they are
involved. Indeed, the Man9-V3 glycopeptide in our crystal
structures was also used to isolate the DH270.6 bnAb by labeling
the BCR of memory B cells from the HIV-1 infected donor12.
The goal of an HIV-1 vaccine is to elicit neutralizing Abs of
signiﬁcant breadth. Eliciting an antibody like DH270.6 would be
more favorable than eliciting one like DH270.3, with a narrower
spectrum of neutralizing activity. Our structures showed that the
R98TH mutation, which is found in many N332-glycan depen-
dent bnAbs (Supplementary Fig. 8) and occurs at a disfavored
AID site, was a critical step in the afﬁnity maturation pathway.
The mutation allowed the conserved residue D115 in the anti-
body heavy chain to interact favorably with the C-mannose
moiety in the D1 arm of N332-Man9, while R98H and L48L, found
in the UCA, DH270.3, and several early intermediates, anchor
D115H in a rotamer that does not allow the glycan contact.
DH270.2, which is close to DH270.3 in the lineage, has lysine at
position 98H, which could in principle form a salt bridge with
D115H, like R98H in the other antibodies. Analogous contacts
with the D1 arm mannose moiety are present in Env complexes
of PGT128 (by D95aL) and PGT124 (by R100H) (Supplementary
Fig. 5C, 5D)9, 11. Loss of neutralization accompanies mutation of
these residues. PGDM21, which has a CDRH3 of the same length
as those of DH270 lineage members, has been reported to bind
gp120 with both high mannose and complex glycans at N332; its
binding also depends on the D1 arm mannose moiety13. The
R98HT mutation could thus have been an important event in the
development of breadth in the DH270 lineage.
Another previously identiﬁed, improbable mutation, G57RH,
which occurred between the UCA and IA4 of the lineage and has
generally not been found in other N332-glycan bnAbs identiﬁed
to date9, 11, 13, 14, 32 (Supplementary Fig. 8), appears to have been
a critical initial step in expansion of the DH270 bnAb lineage12.
The polar hydrogen bonds between R57H and backbone carbo-
nyls in the conserved 322–325 bulge show that an antibody with
shorter CDR loops than those of PGT124 and PGT128 can still
penetrate the glycan shield to make conformation speciﬁc con-
tacts with the Env protein. Other N332-glycan-dependent bnAbs
with short CDR loops have been identiﬁed, e.g. the PCDN anti-
body lineage32. These antibodies have CDRH3 loops that are only
two residues longer than those of the DH270 lineage and have
shorter CDR loops than PGT124 and PGT128 (Supplementary
Fig. 8). Moreover, PCDN antibodies have been shown to have low
levels of autoreactivity. Thus, the correlation of longer CDR loops
with auto- and polyreactivity33–35 may not be a major barrier for
eliciting V3-glycan-directed antibodies.
Like most bnAb lineages, DH270 developed breadth only
several years after infection, at least in part because of the two
improbable somatic mutations needed for speciﬁc anchoring at
two complementary positions on Env. The G57RH mutation,
early in the lineage, allowed IA4 (or an analogous precursor) to
latch onto the V3 loop backbone; the subsequent R98TH muta-
tion in the DH270.6 branch allowed binding to a high mannose
moiety of the N332 glycan. Persistent encounters with antigen
during several years of chronic infection were presumably critical
in selecting for this sequence of low probability mutational events.
Repeated immunization may likewise be essential for bnAb
induction.
Immunizations with Man9-V3 alone have not yielded bnAb
responses24. Man9-V3 may, however, be useful in a prime-boost
format, in which Man9-V3 is used to prime precursors of V3-
glycan B-cell lineages, followed by boosts with multimerized
Man9-V3 to augment T-cell responses or with sequential Envs
found in HIV-1-infected individuals who have developed V3-
glycan bnAbs. Alternatively, it might be useful to use Man9-V3 in
conjunction with a monomer containing a T-cell helper epitope,
such as a glycoconjugate of the non-natural pan DR epitope36, to
improve carbohydrate-speciﬁc antibody responses by immuni-
zation with a glycopeptide.
The Man9-V3 glycopeptide used in these studies maintains a
substantial amount of structure in solution even when not bound
to a speciﬁc antibody, and when bound it accurately mimics the
native conformation, with high afﬁnity for a potentially desired
bnAb such as DH270.6. The structure we determined suggests
ways to design a modiﬁed Man9-V3 with increased stability. For
example, H330 could be replaced with a residue, such as gluta-
mine, that could hydrogen bond with Thr297, to increase stability
of the hairpin (Supplementary Fig. 3C). The absence of dis-
tracting epitopes in Man9-V3 suggests that minimal antigens of
this kind might be suitable candidate immunogens in regimes
involving long-term antigenic exposure.
Methods
Expression and puriﬁcation of DH270 lineage members. The heavy- and light-
chain variable and constant domains of the DH270.3 and DH270.6 Fabs were
cloned into a modiﬁed pVRC-8400 expression vector using Not1 and Nhe1
restriction sites and the tissue plasminogen activator signal sequence. The
DH270.6 scFv was cloned into the same vector as above. The C terminus of the
heavy-chain constructs and scFv contained a noncleavable 6× histidine tag. Site-
directed mutagenesis was performed using manufacturer’s protocols (Stratagene)
to introduce mutations into the CDR regions of DH270.3 and DH270.6 Fabs. Fabs
and the DH270.6 scFv were expressed and puriﬁed as described previously12, 37.
Brieﬂy, Fabs and the DH270.6 scFv were expressed using transient transfection of
HEK 293T cells (ATCC: CRL-3216) using linear polyethylenimine (PEI) following
the manufacturer’s suggested protocol. After 5 days of expression, supernatants
were clariﬁed by centrifugation. His-tagged Fabs were loaded onto Ni-NTA
superﬂow resin (Qiagen) preequilibrated with Buffer A (10 mM Tris, pH 7.5, 100
mM NaCl), washed with Buffer A+ 10 mM imidazole, and eluted with Buffer A+
350 mM imidazole. Fabs were then puriﬁed by gel ﬁltration chromatography in
Buffer A using a superdex 200 analytical column (GE Healthcare).
Synthesis of Man9-biotin, Man9-V3-biotin and Man9-V3. Man9-biotin and
Man9-V3-biotin were synthesized as described earlier24. Man9-V3 was synthesized
following an identical strategy as previously described. A full description of the
chemical synthesis is detailed in the Supplementary Methods. Brieﬂy, using our
one-ﬂask aspartylation/deprotection protocol, Man9GlcNAc2 glycosyl amine 1 was
joined to the free carboxylic acid side chain at position 301 on fragment 2 and at
position 332 on fragment 3, followed by triﬂuoroacetic acid treatment to provide
glycopeptide thioester 4 and N-terminal cysteinyl glycopeptide 5. These two
fragments were then joined by native chemical ligation immediately followed by
cyclization via disulﬁde formation to afford Man9-V3 (6).
Crystallization, structure determination, and reﬁnement. The His-tagged
DH270.3 Fab was mixed with 6 molar excess of biotinylated-Man9 glycan at a ﬁnal
complex concentration of 25 mg/ml and the DH270.6 scFv was mixed with 3 molar
excess of Man9-V3 at a ﬁnal complex concentration of 20 mg/ml for crystallization
trials. Crystals were grown in 96-well format using hanging drop vapor diffusion
and appeared after 24–48 h at 20 °C. Crystals were obtained in the following
conditions: 30% PEG 8000, 10 mM CHES, pH 9.0 and 1M NaCl for the DH270.6-
Man9-V3 complex; and 1M Na/K phosphate, pH 5.6 for the DH270.3-Man9
complex. All crystals were harvested and cryoprotected by the addition of 20–25%
glycerol to the reservoir solution and then ﬂash-cooled in liquid nitrogen.
Diffraction data were obtained at 100 K from beam line 24-ID-E at the
Advanced Photon Source using a single wavelength. Data sets from individual
crystals were processed with XDS38. Molecular replacement calculations for the
free scFv and Fab were carried out with PHASER39, using published DH270.6 and
DH270.3, respectively, (Protein Data Bank (PDB) ID 5TQA and 5TPL) as the
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starting models. The Fab model was separated into its variable and constant
domains for molecular replacement.
Reﬁnement was carried out with PHENIX40, and all model modiﬁcations were
carried out with Coot41. During reﬁnement, maps were generated from
combinations of positional, group B-factor, and TLS (translation/libration/screw)
reﬁnement algorithms. Secondary-structure restraints were included at all stages.
Structure validations were performed periodically during reﬁnement using the
MolProbity server42. The ﬁnal reﬁnement statistics are summarized in Table 3.
Expression and puriﬁcation of Envs. The SOSIP.664 constructs were cloned into
the same pVRC-8400 vector described above for Fabs and any mutations were
added by site-directed mutagenesis using manufacturer’s protocols (Stratagene).
SOSIP.664 constructs were transfected along with a plasmid encoding the cellular
protease furin at a 3:1 Env:furin ratio in 293F cells, adapted to grow in suspension
from HEK293T cells (ATCC: CRL-3216). The expression construct of furin was
kindly provided by Bing Chen (Boston Children’s Hospital, Boston, MA). The cells
were allowed to express soluble SOSIP trimers for 5–7 days, and gp120 monomers
were expressed for 5 days. Culture supernatants were collected and cells were
removed by centrifugation at 3800 × g for 20 min, and ﬁltered with a 0.2 µm pore
size ﬁlter. Envs were puriﬁed by ﬂowing the supernatant over a lectin (Galanthus
nivalis) afﬁnity chromatography column overnight at 4 °C. The lectin column was
washed with 1× PBS, followed by a second wash with 1× PBS and 0.5 M NaCl and
proteins were eluted with 1× PBS supplemented with 0.5 M methyl-α-D-manno-
pyranoside and 0.5 M NaCl. The eluate was concentrated and loaded onto a
Superdex 200 10/300 GL column (GE Life Sciences) pre-equilibrated in a buffer of
2.5 mM Tris, pH 7.5, 350 mM NaCl and 0.02% sodium azide for BLI and in 10 mM
Hepes, pH 8.0, 150 mM NaCl and 0.02% sodium azide for negative stain EM, to
separate the trimer-size oligomers from aggregates and gp140 monomers and to
separate gp120 monomers from aggregates.
Electron microscopy. Puriﬁed 92BR SOSIP.664 trimer was incubated with a 6
molar excess of DH270.6 Fab at 4 °C for 1.5 h. A 2.5 µl aliquot containing ∼0.01
mg/ml of the Fab-92BR SOSIP.664 complex was applied for 30 s onto a carbon-
coated 400 Cu mesh grid that had been glow discharged at 5 mA for 2 min, fol-
lowed by negative staining with 0.7% uranyl formate for 20 s. Samples were imaged
using a FEI Tecnai T12 microscope operated at 120 kV and a magniﬁcation of
×52,000, yielding a pixel size of 2.13 Å at the specimen plane. Images were acquired
with a Gatan 2 K CCD camera using a nominal defocus of 1500 nm at 10° tilt
increments, up to 50°. The tilts provided additional particle orientations to improve
the image reconstructions.
Negative stain image processing and 3D reconstruction. Particles were picked
semi-automatically using EMAN2 and put into a particle stack. Initial, reference-
free, two-dimensional (2D) class averages were calculated, and particles corre-
sponding to complexes (with three Fabs bound) were selected into a substack for
determination of an initial model. The initial model was calculated in EMAN2
using threefold symmetry and EMAN2 was used for subsequent reﬁnement using
threefold symmetry. In total, 12,941 particles were included in the ﬁnal recon-
struction for the 3D average of 92BR SOSIP.664 trimer complex with DH270.6.
The resolution of the ﬁnal model was estimated using a Fourier Shell Correlation
(FSC) cut-off of 0.5.
Model ﬁtting into the EM reconstructions. The cryo-EM structure of PGT128-
liganded BG505 SOSIP.664 (PDB ID: 5ACO) and crystal structure of DH270.6
were placed by inspection into the EM density and reﬁned by using the UCSF
Chimera ‘Fit in map’ function.
Sample preparation for the NMR experiments. Man9-V3 was dissolved in 50
mM phosphate (Pi) buffer (pH 7.5) to a ﬁnal concentration of ~1 mM in 360 μl.
Ten percent (v/v) D2O was added for the NMR lock. DTT was added to a ﬁnal
concentration of 20 mM to reduce the disulﬁde bond.
NMR data acquisition, processing and analysis. The NMR experiments were
performed at 14.1 T on a Bruker Avance III HD spectrometer operating at 600.13
MHz 1H, 150.90 MHz 13C, and 60.81 MHz 15N frequencies, equipped with a
cryogenically cooled probe head. All data were collected at 298.0 K. The NMR 1D
data sets were processed and analyzed using nmrPipe and nmrDraw, respectively43.
Biolayer interferometry. Kinetic measurements of Fab binding to the SOSIP.664
constructs were carried out using the Octet QKe system (ForteBio); 0.2 mg/ml of
each His-tagged Fab was immobilized onto a anti-Human Fab-CH1 biosensor until
it reached saturation. The SOSIP.664 trimers were tested at concentrations of 0.1
μM to 0.6 μM. A reference sample of buffer alone was used to account for any
signal drift that was observed during the experiment. Association and dissociation
were each monitored for 5 min. All experiments were conducted in the Octet
instrument with agitation at 1000 rpm.
Measurements of the kinetics of DH270.6 Fab binding to Man9-V3 and gp120
were carried out using a BLItz instrument (ForteBio). To measure DH270.6
binding to Man9-V3, 0.2 mg/ml of biotinylated Man9-V3 was immobilized on a
streptavidin biosensor at saturation. To measure gp120 binding to the DH270.6
antibody, 0.2 mg/ml of DH270.6 Fab was immobilized on an anti-Human Fab-CH1
biosensor at saturation. The binding of Man9-V3 and gp120 were tested at Fab
concentrations of 40, 15, 5, 1.5, and 0.25 μM, and gp120 concentrations of 25, 15, 5,
1.5, and 0.25 μM, respectively, at 22 °C. Association and dissociation were each
monitored for 5 min.
Analyses were performed using nonlinear regression curve ﬁtting using the
Graphpad Prism software, version 7.
Antibody sequence analysis. Probabilities of amino acid mutations prior to
selection were calculated using the ARMADiLLO program44. Brieﬂy, ARMA-
DiLLO simulates the somatic hypermutation process and uses these simulations to
estimate the probability of an amino acid substitution occurring, in the absence of
selection, from the unmutated common ancestor given the number of mutations
observed in the antibody of interest. Reconstruction of the DH270 clonal genealogy
and corresponding clonal lineage tree was generated with the software package
Cloanalyst45, 46.
Protein structure analysis and graphical representations. The complexes
analyzed in this study were superposed by least squares ﬁtting in Coot or PyMol.
All graphical representations with protein crystal structures, including stereo
images, were made using PyMol.
Data availability. Coordinates and structure factors for Fab DH270.3, bound with
Man9 glycan, and DH270.6 scFv, bound with Man9-V3, have been deposited in the
Protein Data Bank with accession code 6CBJ, and 6CBP, respectively. Sequences
for the DH270.3 and DH270.6 immunoglobulin chains have been deposited pre-
viously (Genbank accession codes KY354944, KY354957, KY354948, and
KY354961). Probabilities of amino acid mutations were calculated using the
ARMADiLLO program (Preprint at https://www.biorxiv.org/content/early/2018/
02/09/262592, 02092018, https://doi.org/10.1101/262592). All other data support-
ing the ﬁndings of this study are available within the article and its Supplementary
Information ﬁles, or are available from the authors upon request.
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Table 3 Crystallographic statistics
DH270.6-Man9-V3 DH270.3-Man9
Data collection
Resolution (Å) 60.14–2.17 (2.25–2.17) 64.04–2.85
(2.95–2.85)
Space group P 41 2 2 I 41
Unit cell a,b,c (Å) 68.0, 68.0, 128.8 128.1, 128.1, 91.9
Unit cell α, β, γ (°) 90, 90, 90 90, 90, 90
Total reﬂections 77,943 28,007
Unique reﬂections 15,878 17,375
Redundancy 4.9 (4.3) 3.8 (3.8)
Completeness (%) 95.1 (96.2) 99.6 (99.7)
<I/σI> 7.65 (1.12) 11.66 (1.35)
Rmerge 22.7 (149.7) 13.0 (105.7)
Reﬁnement
Rwork/Rfree (%) 22.1/27.8 (31.9/37.7) 20.4/23.1
(29.4/33.4)
No. atoms
Protein 2019 3256
Ligand 155 132
Water 96 8
R.M.S. deviations
Bond lengths (Å) 0.005 0.006
Bond angles (°) 1.04 1.02
B-factors (Å2)
Protein 38.00 62.30
Ligand 30.00 43.40
Solvent 41.00 39.50
Statistics for the highest-resolution shell are shown in parentheses
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